THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for ...

Focal One Robotic HIFU Patient Story Featured on Health Uncensored with Dr. Drew on Lifetime Network ...

LONDON, June 7, 2017 /PRNewswire/ -- High-Intensity Focused Ultrasound (HIFU) is an FDA-approved, minimally invasive therapeutic technology with the potential to transform the treatment of many ...

In 2015, Houston Methodist Hospital made the decision to invest in a medical technology that had not yet been approved by the US Food & Drug Administration. The procedure, called High Intensity ...

LYON, France, October 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patients have been treated in a Phase I/II study ...

LYON, France, January 31, 2022 -- EDAP TMS SA (EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced positive clinical results from the Endo-HIFU-R1 Phase 2 study ...

LYON, France,January 29, 2020 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the University of Miami Sylvester Comprehensive ...

DUBLIN, Aug. 3, 2023 /PRNewswire/ -- The "Global High Intensity Focused Ultrasound (HIFU) Therapy Market, Company Profiles, Product Analysis & Recent Development - Forecast to 2030" report has been ...

LYON, France, November 30, 2022-- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the Company has received approval from French ...

Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023 Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023 U.S. Focal One HIFU ...

LYON, France, March 4, 2024 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, announced today that its Focal One platform has been granted Breakthrough Device designation by ...